GlassScriptPhysician profile
Jenna Hartman
NPI 1619359130
$4,545.08
in general payments reported to CMS, 2019-2025
22 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.74 · 2021: $320 · 2022: $602 · 2023: $703 · 2024: $1,416 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,734.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $684.83 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $426.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $376.58 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $373.98 | 2021-2025 | |
| Abbott Laboratories | $180.35 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.45 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $138.58 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $73.16 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $67.10 | 2022-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $63.30 | 2021 | |
| Axsome Therapeutics, INC. | $48.89 | 2025 | Symbravo |
| Sanofi Pasteur INC. | $32.96 | 2023-2025 | |
| Amgen INC. | $30.81 | 2025 | Repatha |
| Janssen Pharmaceuticals, INC | $29.95 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.57 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.76 | 2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $16.60 | 2022 | |
| Astellas Pharma US INC | $14.96 | 2024 | Veozah |
| Corcept Therapeutics | $14.73 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.